Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02968 |
| Species: | Mus musculus |
| Position : | chr3:3103577-3104077 |
| Year: | 2020 |
| Title: | NFIA differentially controls adipogenic and myogenic gene program through distinct pathways to ensure brown and beige adipocyte differentiation |
| Genome Build: | mm10 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| Disease Name: | -- |
| PMID: | 32991700 |
| MONDO: | |
| Tissue: | Adipose tissue |
| Tissue Ontology ID: | UBERON:0001013 |
| Cell Source: | 3T3-F442A preadipocyte |
| CVCL ID: | CVCL_5246 |
| Cell Type: | preadipocyte |
| Cell Ontology ID: | CL:0000136 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| High Throughput Method: | FAIRE-seq, ChIP-seq, RNA-seq |
| Low Throughput Method: | ChIP-RT-qPCR, FAIRE-RT-qPCR, CRISPRi, Luciferase Reporter Assay, RT-RT-qPCR, Oil-Red-O Staining |
| Target gene : | Pparg |
| TF name : | Nfia |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| Nfia | FOXA1 transcription factor network | pid | 45 |
| Nfia | RNA Polymerase III Abortive And Retractive Initiation | reactome | 41 |
| Nfia | RNA Polymerase III Transcription Termination | reactome | 23 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_02967 | chr3:3103577-3104077 | Skeletal muscle | myoblast | -- |